Our first product to market:


Our lead product under development, REPELWRAP™, is a protective surface coating film that, due to its repelling properties, prevents adhesion of pathogens and reduces their transmission on surfaces prone to contamination. REPELWRAP is being developed to protect high touch surfaces in healthcare and other high traffic public touchpoints.

  • Reduces viral titers > 99% of Covid-19 related strains.(1)
  • Reduces transfer of Escherichia coli by 20-fold.(1)
  • Reduces colony formation of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa by >85%.(2)
  • Successfully repels blood (2)
  • Maintains robust repelling properties after being subjected to various physical and mechanical forces. (2)
  • Holds repelling properties under strain and while conforming to different form factors (bent or unbent).(2)

Once fully developed, the Company intends to initially target REPELWRAPTM film towards healthcare settings (i.e., hospitals, long-term care, senior’s residences, clinics) and high traffic public touchpoints (i.e., transportation, hospitality, stadiums/arenas/malls, restaurants, schools, business offices) prone contamination. We intend to commercialize REPELWRAP™ through distributor partnerships.

REPELWRAP™ film will be first launched in the Canadian market, conditional on successful commercial scale-up.

We are also actively exploring additional applications using our nanotechnology, including development of:

  • Enhancements to the current REPELWRAP™ film prototype to create follow-on films including films with both repelling and killing properties.
  • Coating of catheters to prevent catheter-related bacterial biofilm formation and occlusion.

(1) Source: ACS Appl. Mater. Interfaces 2022, 14, 11068-11077.
(2) Source: ACS Nano. 2020 Jan 28, 14 (1) 454-465.